VIEW ALL RESEARCH-GROUP

Tumor angiogenesis group
Casanovas’ Lab

DESCRIPTION

Mechanisms of resistance to antiangiogenic therapies.
Therapeutic studies in Kidney Cancer murine models, both PDOX and syngenic.
Therapeutic studies in pancreatic NeuroEndocrine tumors.
Discovery of non-invasive biomarkers in clinical trials with antiangiogenics.

Our research group at the ProCURE Program (Catalan Institute of Oncology) and OncoBell Program (IDIBELL) is focused on determining the consequences of adaptation and resistance to anti-angiogenic cancer therapy. For that we use translational research in murine models of cancer, particularly Kindey Cancer PDOX models and NeuroEndocrine transgenic models to study in vivo mechanisms of adaptation to anti-angiogenics, and validate our findings using clinical samples from our hospital and collaborating institutions.
Our scientific achievements have been published in prestigious journals in the field of cancer research with numerous “preview”, “highlight” or commentary articles in high impact scientific journals. Furthermore, we have an important international position in the field of antitumor therapies and angiogenic resistance mechanisms.

Felix-Joan Peix

Young investigators

Laura Puigròs

Young investigators

Jessica Videira

Young investigators

Maria Del Mar Martinez Lozano

Support staff

Irene Ortiz-Rubio

Researchers

Laura Bernaus

Support staff

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

/in /by

Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027. ABSTRACT Multiple angiogenesis inhibitors have been therapeutically validated in preclinical cancer models, and several in clinical trials. Here we report that angiogenesis inhibitors targeting the VEGF pathway demonstrate antitumor effects in mouse models of pancreatic neuroendocrine carcinoma and glioblastoma but concomitantly elicit tumor adaptation and progression to stages […]

Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

/in /by

Mol Cancer Ther. 2008 Mar;7(3):638-47. doi: 10.1158/1535-7163.MCT-07-2122. ABSTRACT Gemcitabine shows a marked antitumor effect as a result of its cytotoxic action toward proliferative cells. In this article, we aim to investigate the potential antitumor and antiangiogenic effect of gemcitabine following a metronomic schedule that involves the regular administration of cytotoxic drugs at doses lower than […]

New drug development in digestive neuroendocrine tumors

/in /by

Ann Oncol. 2007 Aug;18(8):1307-13. doi: 10.1093/annonc/mdm009. Epub 2007 Feb 13. ABSTRACT The traditional cytotoxic agents are of limited efficacy in the treatment of neuroendocrine tumors of the gastrointestinal tract (NETs). Recent investigations have brought up a number of biological features in this family of neoplasms that could represent targets for anticancer treatment. NETs seem to […]

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

/in /by

Cancer Cell. 2005 Oct;8(4):299-309. doi: 10.1016/j.ccr.2005.09.005. ABSTRACT Function-blocking antibodies to VEGF receptors R1 and R2 were used to probe their roles in controlling angiogenesis in a mouse model of pancreatic islet carcinogenesis. Inhibition of VEGFR2 but not VEGFR1 markedly disrupted angiogenic switching, persistent angiogenesis, and initial tumor growth. In late-stage tumors, phenotypic resistance to VEGFR2 […]

How to define intermediate stage in Hodgkin’s lymphoma?

/in /by

Eur J Haematol Suppl. 2005 Jul;(66):111-4. doi: 10.1111/j.1600-0609.2005.00463.x. ABSTRACT BACKGROUND: Intermediate or unfavourable stage Hodgkin’s lymphoma (HL) definition relies upon at least three different scoring systems defined by cooperative groups (EORTC, GHSG and Canadian-ECOG). We aimed to investigate their efficacy and their correlation with International Prognostic Score (IPS) for advanced HL. PATIENTS AND METHODS: We […]

  1. MICIU PID2022-142386OB-I00 Disección de los mecanismos de Plaquetas y genes de Coagulación en la metástasis del Cancer de Riñón Oriol Casanovas 325.000,00 €PREP2022-000672 Disección de los mecanismos de Plaquetas y genes de Coagulación en la metástasis del Cancer de Riñón Oriol Casanovas 111.758,00 €
    Proyecto PID2022-142386OB-I00 financiado por MCIU/AEI/10.13039/501100011033 y por FEDER, UE
  2. MTV3 201910-30 Identification of Kidney Cancer progression targets and biomarkers through CRISPRengineered organoids and xenograft mouse models Oriol Casanovas 136.250,00 €
  3. MICIU PID2019-107557RB-I00 Targeteando la Coagulación en la formación de metástasis en cáncer renal Oriol Casanovas 145.200,00 €
    Proyecto PID2019-107557RB-I00 financiado por MICIU/AEI /10.13039/501100011033
  4. AGAUR 2021 SGR 01289 Interacció Tumor Estroma i Resistència Terapèutica – ITERT Oriol Casanovas 40.000,00 €

    Tech Transfer Projects

  5. MICIU CPP2023-010718 Opening a New Era in Hepatocellular Carcinoma by a Novel Blood Biomarker for Individual Selection of Treatment (PersonalHCC) Oriol Casanovas 514.874,00 €
    Proyecto CPP2023-010718 financiado por MICIU/AEI/10.13039/501100011033 y por FEDER, UE.
  6. AGAUR 2022 DI 00052 Inhibiting Cannibalism to Fight Resistant Tumors Oriol Casanovas 33.960,00 €
  7. MICIU PDC2021-121308-I00 Desarrollo de un nuevo biomarcador y su ‘kit’ prototipo para predecir la Respuesta Agresiva en Cancer Oriol Casanovas 132.250,00 €
    Proyecto PDC2021-121308-I00 financiado por MCIU/AEI/10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR
  8. ISCIII DTS21/00163 Angiotheragnostics: Desarrollo de un nuevo tratamiento con su biomarcador de selección de pacientes para pacientes con cáncer colorectal avanzado. Oriol Casanovas 149.600,00 €


International:
Douglas Hanahan, ISREC

Gabriele Bergers, KULeuven

Masahiro Inoue, Univ.Osaka

Kristian Pietras, Karolinska I.

Enrico Giraudo, IRCC

Stefano Indraccolo, IOV


National:

Joan Carles, VHIO

Cristina Suárez, VHIO

Maria Ochoa, ICO

August Vidal, HUB

Ramon Salazar, ICO

X García del Muro, ICO

Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

Sureda’s & Farre’s LabGrup-Hematoligia-webViñals's labViñals’s lab